Objectives: To examine antimicrobial susceptibility patterns and predictors of resistance among Shigella isolates in New South Wales (NSW), Australia during 2013-14 with emphasis on azithromycin.
Introduction
Shigellosis is an acute enteric infection caused by one of four Shigella species: Shigella dysenteriae, Shigella flexneri, Shigella boydii or Shigella sonnei, which can be further divided into subgroups. All subgroups cause a similar syndrome of diarrhoea, fever and nausea, and stools may contain blood and mucus; however, both disease severity and the geographical distribution of the subgroups differ. 1 Shigellosis is the third most commonly notified enteric bacterial infection reported to public health authorities in Australia. In 2012, there were 547 cases of shigellosis notified in Australia. Shigella spp. are easily transmitted from person to person via the faecaloral route including through contaminated food and water, as well as close personal or sexual contact with faecal exposure. 2 While shigellosis is typically self-limiting, treatment with appropriate antimicrobial therapy can shorten the duration of illness and bacterial shedding, and therefore prevent transmission. 3 There is evidence of increasing resistance to various antimicrobials in Shigella isolates from international studies, and shigellosis can be acquired during travel. 4, 5 However, there is a relative lack of published research on this issue in an Australian context, particularly with reference to azithromycin resistance. 6 Knowledge of antimicrobial susceptibility profiles of prevalent strains can assist clinicians' decision-making regarding empirical treatment of cases. The current Australian and IDSA therapeutic guidelines recommend prescription of either co-trimoxazole or quinolone therapy for suspected or proven shigellosis. 7, 8 However, the Australian guidelines and the US CDC do comment that quinolone resistance is increasing and recommend azithromycin as an alternative option. 7, 9 The aim of this study was to describe antimicrobial susceptibility patterns among Shigella isolates in New South Wales (NSW), Australia during 2013-14 and to identify predictors of resistance with the use of epidemiological data from the NSW Notifiable Conditions Information Management System (NCIMS).
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Methods

Ethics
The study used routinely collected surveillance data from NCIMS collected by NSW Health for the purposes of analysis and reporting, for which ethics approval was not required.
Data sources
Notification of shigellosis cases to public health authorities is required under the NSW Public Health Act. Confirmed cases are routinely recorded in the NCIMS administered by NSW Health. During the study period, a notified case was classified as 'confirmed' if there was definitive laboratory evidence (isolation or detection of Shigella species).
Public health unit (PHU) staff investigate all cases of shigellosis notified to NSW Health. 10 During this process PHU staff attempt to interview the case and gather self-reported information on risk factors, which are recorded in the NCIMS. The risk factors used in this study were sex, age, acquired overseas status, region of acquisition and sex with faecal exposure. Case history of sex with faecal exposure is a designated field recorded as a risk factor in the NCIMS. MSM status may also be included in patient's notes but is not a designated field in the NCIMS and thus may not be as complete as the variable 'sex with faecal exposure'. We used the risk factor 'sex with faecal exposure' for this reason. However, some patients may choose not to report their 'sex with faecal exposure' status for personal reasons.
Study population
Eligible patients were those notified to NSW Health as confirmed shigellosis cases whose specimens were received by the Enteric Reference Laboratory 
Statistical analysis
To facilitate statistical analyses and reflect laboratory practice, all isolates that had intermediate susceptibility were coded as non-susceptible. We examined the relationship between risk factors for illness and patterns of antimicrobial resistance. We analysed frequency and proportions of risk factors by both Shigella species and antimicrobial resistance. Fisher's exact test was used to assess differences between comparison groups. Univariate logistic regression was used to model the reported risk factors against antimicrobial resistance for azithromycin, ampicillin, ciprofloxacin and co-trimoxazole. We performed additional logistic regression models at the species level where possible to assess differences in resistance.
We examined frequencies of resistance profiles for azithromycin, ciprofloxacin, co-trimoxazole and ampicillin by creating an array of resistance and susceptibility for each isolate to those drugs. All statistical analysis was performed using SAS/STAT software, version 9.3 of the SAS system for Windows.
Laboratory methods
All microbiology laboratories in NSW (public and private) routinely refer isolates of Shigella spp. to the ERL for NSW, located at the ICPMR. Consecutive isolates collected from 1 May 2013 to 30 April 2014 were included in this study. Submitted isolates are analysed progressively via slide agglutination with initially polyvalent then appropriate monovalent antisera (Denka Seiken) where agglutination confirms the presence of the tested serotype.
Susceptibility testing, including ciprofloxacin, was performed using the BD Phoenix automated broth microdilution instrument and interpreted according to CLSI criteria, except for four isolates that failed repeatedly and were tested by disc diffusion according to CLSI protocols. MIC testing was performed according to CLSI specifications. Azithromycin (all isolates) and ciprofloxacin (109/160 isolates) MICs were determined by zone of inhibition using the Etest (bioMérieux), with a 0.5 McFarland suspension inoculated as a three-way lawn, incubated for 24 h on Mueller-Hinton agar at 35 C in an aerobic atmosphere. A breakpoint of 16 mg/L was used for susceptibility to azithromycin, in line with previous investigators.
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PCR for mphA was carried out using previously published primers 12 from DNA extracted with the NucliSENS easyMAG system according to the manufacturer's instructions (bioMérieux). In brief, PCR was performed in a 25 lL reaction containing Hot Start PCR Master Mix (Qiagen Inc.), 200 nM primers and a 1:100 dilution of sample extract. Cycle conditions were polymerase activation at 95 C for 15 min, followed by 45 cycles of amplification at 96 C for 15 s, 42 C for 1 min and 72 C for 1 min. PCR was considered positive if a band of expected size (837 bp) was seen on amplicon detection by agarose gel electrophoresis and SYBRsafe staining.
Results
A total of 160 isolates from 159 patients was obtained from the NSW reference laboratory with collection dates from 1 May 2013 to 30 April 2014. One patient was found to have had two separate episodes of shigellosis and one isolate from each event was included in this analysis. Demographic data are contained in Table 1 . There were 2.8 times as many men (73.8%) as women (26.2%) notified with shigellosis and more than half (56.9%) of shigellosis cases were acquired locally (Table 1) . Of cases acquired overseas, half were acquired in South Asia (25.0%) or South-East Asia (25.0%). Of the cases where information regarding symptoms was recorded (n " 73), the median duration of illness was 7 days (range 1-42 days) with a mean of 9.3 days (95% CI 7.5-11.2).
More than one-third (36.3%) of people with shigellosis stated that they had sex with faecal exposure prior to developing illness. Of those 58 people (all male) who stated that they had sex with faecal exposure, 57 also stated that they were MSM. Males (74.0%) were more than twice as likely to have acquired shigellosis locally as females (33.3%; P , 0.0001). Of males with local acquisition, 54 (70.1%) reported having sex with faecal exposure prior to illness. Univariate logistic regression showed that people with locally acquired shigellosis were 2.2 times more likely to have a ciprofloxacin-resistant strain than people with shigellosis acquired overseas (OR 2.2, 95% CI 1.0-4.7, P " 0.04). We found resistance to ciprofloxacin among isolates acquired in South Asia (61.5%), South-East Asia (23.1%) and Australia (41.8%), but did not find resistance among isolates acquired in other regions (Table 1 ).
Resistance data are described by demographics in Table 1 , by Shigella species in Table 2 and by cumulative resistance in Figure 1 . Azithromycin MIC frequency by species is described in Figure 2 .
Azithromycin resistance was detected in 21 isolates (13/21 were S. flexneri 3a, but representing two different antibiograms of 11 and 2 isolates each) and each of these was shown by PCR to carry the mphA resistance gene, encoding a phosphotransferase. The rates of resistance by species to the four most important oral agents are described in Table 2 . Of the 21 isolates that were resistant to azithromycin, the majority (90.5%) were susceptible to ciprofloxacin (Figure 1 ). Univariate logistic regression showed that males were 8.4 times more likely to have an azithromycin-resistant strain than females (95% CI 1.7-153.6, P " 0.04) ( Table 1 ). The MIC frequencies of S. sonnei and S. flexneri to azithromycin are shown in Figure 2 .
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Multiresistance was common; there were 12 different antibiograms detected in relation to the frequently prescribed oral antibiotics, 8 with more than five isolates, and 7 showing multiresistance ( Figure 1 ). We found that about one in three (35.0%) isolates tested were resistant to both ciprofloxacin and cotrimoxazole, and one isolate was resistant to azithromycin, ciprofloxacin, co-trimoxazole and ampicillin, as well as ceftriaxone (Figure 1) . Including this isolate, we found three isolates (2.0%) that were resistant to ceftriaxone. One was typed as S. flexneri Biotype 2a and the other two were typed as S. sonnei Biotype G. Tetracycline resistance was detected in 127 isolates (although all isolates were susceptible to tigecycline) and chloramphenicol resistance in 114. All isolates were susceptible to meropenem and colistin.
There was complete concordance in susceptibility designation to ciprofloxacin between the BD Phoenix and Etest, with no isolate differing by more than one doubling dilution across the range reported by the Phoenix test (,0.13 to .2 mg/L) and no designation errors.
Discussion
This study provides comprehensive data on the antimicrobial susceptibility of Shigella species in a low-prevalence setting. As expected, the data contain a mixture of sexually and non-sexually acquired, locally acquired and travel-associated infections (see Table 1 ). Treatment of shigellosis is aimed at terminating symptoms and reducing the spread of this highly infectious organism. 2, 3 Our results show high rates of resistance to currently recommended antimicrobial therapies, including ciprofloxacin (35.0%) and co-trimoxazole (76.3%). The majority of isolates (86.9%) were susceptible to azithromycin. These results have led to advice to reconsider current Australian therapeutic guidelines, which are very similar to international guidelines from the USA. The total includes all Shigella isolates obtained from the NSW reference laboratory with collection dates from 1 May 2013 to 30 April 2014. The first isolate received by the reference laboratory for each illness event was used in this study. Subsequent isolates were excluded where patients had multiple specimens collected for one illness event.
b Denotes statistically significant association between risk factor and resistance at the P " 0.05 level using Fisher's exact test. c Fifty-seven of 58 people who stated having sex with faecal exposure prior to illness onset also stated that they were MSM.
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Our study indicates that in our low-prevalence setting, males were more likely to be infected with an azithromycin-resistant strain than females (OR 8.4, 95% CI 1.7-153.6, P " 0.04). The most likely explanation for this finding is association with sexual acquisition among MSM in both Asia and Australia. In particular, there is an ongoing outbreak of a clonal azithromycin-resistant S. flexneri subtype 3a in MSM in Sydney (being by far the most populous city in NSW, where a majority of the isolates from this study originate), and worldwide. [13] [14] [15] Predominance of this outbreak strain also explains the increased rate of azithromycin resistance seen in S. flexneri compared with S. sonnei. Sex with faecal exposure is not an independent risk factor for azithromycin resistance in our analysis; however, the self-reported nature of exposure under current public health protocols is likely to lead to under-attribution of this risk factor.
Neither CLSI nor EUCAST publish clinical breakpoints for azithromycin in Shigella species. Previous investigators suggest an ecological cut-off of 16 mg/L is appropriate for WT Shigella, while CLSI suggest 8 mg/L for S. flexneri and 16 mg/L for S. sonnei, 16 which is supported by our results (Figure 2) . Specifically, in our data, S. flexneri (MIC 50 4 mg/L) has a lower MIC distribution than S. sonnei (MIC 50 8 mg/L), which is similar to the limited data available in the EUCAST ecological cut-off database. 17 Both species have bimodal peaks at below 16 mg/L and at 256 mg/L, and all isolates with an MIC .256 mg/L contained mphA. The differential susceptibility to azithromycin of these species has not been comprehensively reported previously. In 1999, Stock and Wiedemann 18 tested 29 S. flexneri and 37 S. sonnei with only four isolates having an MIC of 8 mg/L, and none having an MIC of 16 mg/L; however, Howie et al. 19 showed a vast majority of 392 
The total includes Shigella isolates obtained from the NSW reference laboratory with collection dates from 1 May 2013 to 30 April 2014. The first isolate received by the reference laboratory for each illness event was used in this study. Subsequent isolates were excluded where patients had multiple specimens collected for one illness event.
a Serogroups: 1a " 2, 1b " 6, 1c " 2, 2a " 7, 2b " 3, 3a " 14, 3b " 2, 4"2, 6"1, untyped " 9.
b Denotes statistically significant difference between resistance of S. flexneri and S. sonnei at P , 0.001 level using Fisher's exact test. S. boydii and S. dysenteriae were excluded from this test due to insufficient numbers of isolates. Brown et al. 20 also showed a significant minority of Shigella isolates from Bangladesh had an MIC 8 mg/L, unfortunately their data did not describe MIC by species. Although plasmid-borne mphA is the dominant (and readily transferable) mechanism of azithromycin resistance in Shigella species, these observations suggest that a non-mphA-mediated reduced-susceptibility mechanism is present in S. sonnei, raising the spectre of future 'MIC creep' in this species due to serial resistance mutations. 15, 19, [21] [22] [23] It is not clear at what azithromycin MIC treatment failure is likely to occur, as the suggested breakpoint of 16 mg/L is based on ecological cut-off data rather than clinical observation, and the concentration of azithromycin in tissues may mean that isolates with MICs .16 mg/L respond clinically. However, there are documented failures of azithromycin with MICs .256 mg/L 24 and we and others have documented Shigella strains with MICs as low as 64 mg/L that contain mphA, [21] [22] [23] [24] [25] which are theoretically likely to be clinically resistant, further supporting 16 mg/L as an ecological cut-off.
Resistance to ciprofloxacin was only found in isolates acquired from South Asia, South-East Asia or Australia. Isolates acquired elsewhere overseas did not show resistance to ciprofloxacin, a finding that is supported by other Australian data that showed 50% of India-acquired isolates and generally ,10% of isolates acquired from other non-Australian locations were resistant. 6 However, our study (35.2%) does differ substantially from these data (3.8%) in the rate of ampicillin resistance in locally acquired disease, which is not easily explained by the minor time difference of at most 4 years between the isolates. 6 Importation and domestic transmission of S. sonnei resistant to ciprofloxacin from South Asia and South-East Asia has recently been documented in the USA. 5 The excess of ciprofloxacin resistance in NSW-acquired infections compared with infections acquired outside Asia may be due to local transmission of strains acquired in Asia or epidemic spread of, for example, ciprofloxacinresistant S. sonnei G among MSM in NSW. We report that 12 different antibiograms of Shigella species are circulating in NSW, with 7 of them being MDR, based on routine oral therapies alone (see Figure 1 ). Due to restrictions on quinolone use in Australia it is unlikely the high rate of ciprofloxacin resistance found in our study (similar to infections acquired in Asia) has arisen locally. 26 Such a diverse range of resistant strains in a low-prevalence community is more likely to be the result of repeated importation and localspread events rather than locally generated resistance.
Three isolates were found to be ceftriaxone resistant, one S. flexneri 2a and two S. sonnei G, showing that resistance to this agent remains rare in NSW. However, the S. flexneri 2a isolate was also resistant to all oral antibiotics, highlighting the potential for an outbreak of highly resistant shigellosis, particularly among highrisk groups, as has already occurred with the azithromycinresistant S. flexneri 3a in Sydney, Melbourne and elsewhere. 14, 15, 23 A limitation of this study is that the isolates were only sampled for a 1 year period. Therefore, this study cannot show potential year-to-year variation in resistance profiles, such as caused by epidemics among MSM. A further limitation is the potential for referral bias of those patients who have failed therapy, or had a confirmed at-risk contact, for culture, since those patients may be more likely to have a stool sample taken. Potentially, there may also be bias towards successful culture of resistant isolates among those who are already on therapy at the time of sample collection. Such biases towards detection of resistant isolates could mean an overestimate of the true proportion of resistance in the community. Another limitation of this study is that risk factors are selfreported by patients, which may lead to reporting bias, and not all cases had risk factor information ascertained and recorded.
Our study, and those of others, demonstrates that Australia, a developed nation with low prevalence of shigellosis, is clearly not immune from the general increase in resistant Shigella, including azithromycin resistance. 4, 6 The current Australian therapeutic guidelines recommend prescription of either co-trimoxazole or quinolone therapy for suspected or proven shigellosis, but comment that quinolone resistance is increasing in developing countries and recommend azithromycin as an alternative option. 7 Elsewhere, the IDSA guidelines (2001) recommend co-trimoxazole, a fluoroquinolone or azithromycin. 8 In light of increasing resistance to these commonly used agents including azithromycin, and potential for multiresistant Shigella epidemics, ongoing culture and determination of Shigella susceptibility and periodic reconsideration Shigella epidemiology, resistance and treatment JAC of treatment guidelines is warranted. Additional data on clinical outcomes of patients treated with azithromycin to allow standardization of clinical breakpoints will simplify individual treatment and public health management of shigellosis.
